Type 1 Diabetes
Conditions
Keywords
xenotransplantation, type I diabetes, porcine islets
Brief summary
The purpose of this study is to establish the safety of xenotransplantation of DIABECELL(R)\[immunoprotected (alginate-encapsulated) porcine islets\] in patients with established type 1 diabetes mellitus, and to establish preliminary evidence of the efficacy of DIABECELL(R), as measured by a reduction in serial hemoglobin A1c (HbA1C) levels.
Detailed description
Intraperitoneal islet transplantation has the potential to ameliorate type 1 diabetes mellitus and avert the long-term consequences of chronic diabetes which cannot be achieved by conventional insulin treatment. As donor human islets are not available in sufficient numbers, porcine islets are the best alternative source as they are recognised as the most physiologically compatible xenogeneic insulin-producing cells. Although the use of pig-derived cells raises the risk of xenotic infections, this can be minimised by obtaining cells from designated pathogen-free (DPF) animals bred in isolation and monitored to be free of specified pathogens. The worldwide experience to date in more than 200 patients who have received transplants of pig tissue has not demonstrated evidence of transmitted xenotic infections. As animal-derived tissues have to be protected from immune rejection when transplanted into humans, transplants are usually accompanied by immunosuppressive therapy. However, porcine islets are preferably transplanted without the use of immunosuppressive drugs which cause significant morbidity. To protect them from immune rejection, the islets can be encapsulated in alginate microcapsules which permit the inward passage of nutrients and glucose and the outward passage of insulin. Alginate-encapsulated porcine islets transplanted without immunosuppressive drugs have survived rejection for many months in animal studies, and have been retrieved from a diabetic patient over 9.5 years after intraperitoneal transplantation and shown to contain viable islets that stain positive for insulin. DIABECELL® comprises neonatal porcine islets encapsulated in alginate microcapsules. DIABECELL® has been safely transplanted in healthy and diabetic mice, rats, rabbits, dogs and non-human primates. Following DIABECELL® transplants, the requirement for daily insulin was significantly reduced in diabetic rats and non-human primates. The optimal dose and frequency of transplantation of the current DIABECELL® preparation for the treatment of type 1 diabetes in humans can only be determined in clinical trials. The intention of this phase I/IIa clinical trial is to obtain at least 52 weeks safety and preliminary efficacy data in type 1 diabetic patients following transplantation of a single low effective dose of DIABECELL® into the peritoneal cavity.
Interventions
DEVICEDIABECELL(R)
10,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
Sponsors
Diatranz Otsuka Limited
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
35 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Adults (males or females) in the age range 35 to 65 years * Diagnosis of type 1 diabetes mellitus (minimum duration of 5 years) in accordance with the American Diabetes Association's criteria. Patients should have been treated continuously with insulin since diagnosis (Expert Committee on the Diagnosis and Classification of Diabetes Mellitus 2002) * Patients with established brittle type I diabetes mellitus with a well-documented chronic history of severe metabolic instability who cannot achieve acceptable metabolic control without experiencing multiple episodes of severe hypoglycaemia, often with unawareness; or * with degrees of hypoglycaemia, who cannot be adequately managed with intensive insulin therapy alone despite intensive diabetes management delivered by a qualified diabetes team for at least six months prior to enrolment * Patients should have an HbA1C ≥7% and ≤10% calculated as the average of the last four consecutive HbA1C readings during the 8-week baseline run-in period. The difference between the highest and lowest of the four HbA1C reading should be no more than 0.5%. * Plasma C-peptide \<0.2 ng/ml following a glucagon stimulation test (Scheen et al. 1996) * If female, no childbearing capability (those who are more than 2 years postmenopausal or have undergone voluntary sterilisation can be considered for enrolment) * Provision of written informed consent. Patients will be required to agree to comply with all tests and visits specified in the protocol, and they (and their partners/close contacts) will also be required to consent to long-term microbiological monitoring, which is an integral part of the study
Exclusion criteria
* Type 2 diabetes, defined as age of onset \>30 years and/or a history of treatment with oral hypoglycaemic medications and/or insulin resistance (defined as an insulin dose requirement ≥1.2 U/kg/day) * An average HbA1C \< 7% and \>10% during the 8-week baseline run-in period * Body mass index (BMI) ≥30 kg/m2 or ≤20 kg/m2 * Active infection, with plasma C-reactive protein ≥10 mg/L at baseline * Previous receipt of an organ, skin graft, or other tissue transplant from a human or animal donor * Treatment with immunosuppressive medications for another medical condition * Previous history of peritoneal disease or abnormal findings at baseline laparoscopy * Previous abdominal surgery, excluding uncomplicated appendectomy or cholecystectomy * History of pelvic inflammatory disease or endometriosis * Inability to tolerate oral medications or a history of significant malabsorption * HIV antibody and/or risk factors for HIV infection * Positive hepatitis C antibody, positive hepatitis B surface antigen, and hepatitis B core antibody * Kidney disease, defined as serum creatinine \>130 μmol/L in men and \>110 μmol/L in women and/or urinary albumin \>300 mg/L and/or haematuria and/or active urinary sediment or casts * Diabetes microvascular complications defined as untreated, potentially vision-threatening proliferative or pre-proliferative retinopathy or maculopathy; painful peripheral neuropathy; autonomic neuropathy manifesting as postural hypotension; gastroparesis or diabetic enteropathy * Diagnosis of coeliac disease and history of gastrointestinal symptoms including chronic or recurrent diarrhoea, malabsorption, weight loss, and abdominal distension or bloating on exposure to gluten products in the diet * Serious comorbid conditions that are likely to affect participation in the study, including: 1. Previous coronary heart disease manifesting as non-ST elevation myocardial infarction (NSTEMI), Q-wave infarction or unstable angina; coronary artery bypass graft (CABG); or percutaneous angioplasty 2. Previous cerebrovascular disease manifesting as transient ischaemic attacks (TIAs) or stroke 3. Peripheral vascular disease with foot ulcer and/or previous amputation 4. History of New York Heart Association (NYHA) class II, III or IV congestive heart failure (CHF) and/or chronic atrial fibrillation 5. Chronic obstructive pulmonary disease (COPD) or asthma with previous hospitalisation for decompensation; a requirement for mechanical ventilation at any stage; or long-term treatment with oral corticosteroids 6. Liver disease with abnormal liver function tests defined as serum bilirubin ≥20 µmol/L, and/or ALT ≥100 U/L, and/or GGT ≥100 U/L, and/or albumin \<35 g/L 7. Haematological disorders, including haemoglobin ≤110 g/L or platelet count \<80 x 109/L 8. Peptic ulcer disease and/or history of previous gastrointestinal bleeding 9. Malignancy other than basal cell carcinoma 10. History of epilepsy 11. Untreated hypothyroidism 12. Known adrenal insufficiency * History of drug, substance or alcohol abuse * Current oestrogen (e.g. cortisol) therapy * Any factor detected from psychometric evaluation at Visit 2 Pre-Tx during the screening period which may in the opinion of the Clinical Psychologist affect an individual's ability to fully participate in the study * Any other condition that, in the opinion of the Investigator, may interfere with adherence to the study protocol, including dementia, mental illness, or a history of non-adherence to appointments or treatments
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To establish the safety of xenotransplantation of DIABECELL(R) [immunoprotected (alginate-encapsulated) porcine islets] | 52 Weeks |
| To establish preliminary evidence of the efficacy of DIABECELL(R), as measured by a reduction in serial HbA1C levels | 52 weeks |
Secondary
| Measure | Time frame |
|---|---|
| To determine whether DIABECELL(R) causes a reduction in insulin dose | 52 Weeks |
| To establish whether DIABECELL(R) causes an improvement in glucose lability determined from continuous glucose monitoring | 52 Weeks |
| To determine whether DIABECELL(R) causes an improvement in quality-of-life | 52 Weeks |
| To determine whether DIABECELL(R) causes an improvement in endogenous insulin secretion | 52 Weeks |
| To determine whether DIABECELL(R) causes a reduction in hypoglycaemia and nocturnal hypoglycaemia | 52 Weeks |
Countries
New Zealand
Outcome results
None listed